TrialCancer research and treatment2021

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.

Kyung-Hun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.